Transcode Therapeutics Inc (RNAZ) — Tangible Net Worth Ratio
Transcode Therapeutics Inc (RNAZ) has a Tangible Net Worth Ratio of -1005.9% as of March 2026. This metric is calculated by deducting intangible assets ($114.30 Million) from net assets ($10.34 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See working capital to net assets of Transcode Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Transcode Therapeutics Inc Tangible Net Worth Ratio (2021–2025)
This chart shows how Transcode Therapeutics Inc's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2025. As of March 2026, the ratio stands at -1005.9%, reflecting net assets of $10.34 Million with intangible assets of $114.30 Million USD. See operational self-sufficiency of Transcode Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Transcode Therapeutics Inc (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Transcode Therapeutics Inc from 2021 to 2025, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see RNAZ company net worth.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -1005.9% | $10.34 Million | $114.30 Million | $162.40 Million | ▼ -1105.9 pp |
| 2023 | 100.0% | $1.64 Million | $0.00 | $5.17 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $3.24 Million | $0.00 | $7.59 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $20.40 Million | $0.00 | $22.94 Million | — |